| Nipple Aspirate Fluid in Detecting Breast Cancer (NCT03715959) | Ohio State University Comprehensive Cancer Center | 2020-12-10 |
| Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer (NCT04090567) | M.D. Anderson Cancer Center | 2020-07-28 |
| T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer (NCT03554044) | University of California, San Francisco | 2020-02-05 |
| Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer (NCT04081389) | Roswell Park Cancer Institute | 2019-12-06 |
| Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy (NCT03872388) | M.D. Anderson Cancer Center | 2019-09-23 |
| Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted (NCT04185311) | Jonsson Comprehensive Cancer Center | 2019-07-10 |
| Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer (NCT03207529) | M.D. Anderson Cancer Center | 2019-06-07 |
| Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer (NCT03644589) | University of Washington | 2019-04-01 |
| Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis (NCT03691493) | Emory University | 2019-02-08 |
| ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors (NCT03725436) | M.D. Anderson Cancer Center | 2019-01-24 |
| Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer (NCT03599453) | Roswell Park Cancer Institute | 2019-01-09 |
| S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer (NCT03723928) | SWOG Cancer Research Network | 2018-09-17 |
| Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer (NCT03238703) | Fred Hutchinson Cancer Center | 2018-09-01 |
| Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer (NCT03633331) | Alliance for Clinical Trials in Oncology | 2018-08-15 |
| Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer (NCT03377101) | National Cancer Institute (NCI) | 2018-08-07 |
| Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer (NCT03566485) | Vanderbilt-Ingram Cancer Center | 2018-07-10 |
| Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer (NCT03477396) | City of Hope Medical Center | 2018-06-14 |
| Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer (NCT03544125) | OHSU Knight Cancer Institute | 2018-05-03 |
| Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery (NCT03326258) | National Cancer Institute (NCI) | 2018-04-20 |
| Exercise Intervention After Cancer Treatment for Improving Health in Stage II-III Breast Cancer Survivors (NCT03523195) | Fred Hutchinson Cancer Center | 2018-04-18 |
| Radiation Therapy Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer (NCT03359954) | M.D. Anderson Cancer Center | 2017-11-16 |
| IACS-010759 in Advanced Cancers (NCT03291938) | M.D. Anderson Cancer Center | 2017-11-13 |
| Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells (NCT03070002) | Northwestern University | 2017-10-19 |
| Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer (NCT02892734) | Northwestern University | 2017-09-18 |
| Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer (NCT03213041) | Northwestern University | 2017-09-14 |
| Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer (NCT03154190) | Stanford University | 2017-08-08 |
| Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer (NCT03128619) | Jonsson Comprehensive Cancer Center | 2017-08-02 |
| Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer (NCT02860000) | Mayo Clinic | 2017-07-06 |
| Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer (NCT03132467) | M.D. Anderson Cancer Center | 2017-06-13 |
| Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer (NCT03106077) | M.D. Anderson Cancer Center | 2017-06-05 |
| Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer (NCT02971761) | City of Hope Medical Center | 2017-06-01 |
| Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery (NCT03044730) | Northwestern University | 2017-05-25 |
| Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible) (NCT02993068) | M.D. Anderson Cancer Center | 2017-04-18 |
| Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery (NCT02760030) | Ohio State University Comprehensive Cancer Center | 2017-02-16 |
| Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca (NCT02957968) | Virginia Commonwealth University | 2017-01-24 |
| Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy (NCT02945579) | M.D. Anderson Cancer Center | 2017-01-20 |
| DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer (NCT02744053) | M.D. Anderson Cancer Center | 2016-11-07 |
| Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer (NCT02876107) | M.D. Anderson Cancer Center | 2016-10-06 |
| Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission (NCT02780401) | University of Washington | 2016-09-02 |
| Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis (NCT02774681) | Northwestern University | 2016-08-31 |
| Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (NCT02432963) | City of Hope Medical Center | 2016-06-14 |
| Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction (NCT02567396) | National Cancer Institute (NCI) | 2016-06-01 |
| FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy (NCT02398773) | National Cancer Institute (NCI) | 2016-05-04 |
| Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer (NCT02648477) | City of Hope Medical Center | 2016-03-28 |
| Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer (NCT02672475) | Vanderbilt-Ingram Cancer Center | 2016-03-01 |
| Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer (NCT02627430) | National Cancer Institute (NCI) | 2016-03-01 |
| MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer (NCT02536794) | Northwestern University | 2016-01-14 |
| Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy (NCT02445391) | ECOG-ACRIN Cancer Research Group | 2015-10-20 |
| Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors (NCT02401347) | Melinda Telli | 2015-08-01 |
| Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer (NCT02488967) | NRG Oncology | 2015-07-26 |
| 18F-FSPG PET/CT for Cancer Patients on Therapy (NCT02599194) | Andrei Iagaru | 2015-07-01 |
| Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy (NCT02411656) | M.D. Anderson Cancer Center | 2015-06-11 |
| Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer (NCT02457910) | Vanderbilt-Ingram Cancer Center | 2015-06-01 |
| Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer (NCT02282345) | M.D. Anderson Cancer Center | 2015-04-16 |
| mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian (NCT02208375) | M.D. Anderson Cancer Center | 2014-11-11 |
| Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer (NCT02120469) | City of Hope Medical Center | 2014-10-01 |
| Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic (NCT02115282) | National Cancer Institute (NCI) | 2014-03-29 |
| Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer (NCT02037529) | Academic and Community Cancer Research United | 2014-01-17 |
| Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Anti-cancer Therapy (NCT01957514) | University of Washington | 2013-10-28 |
| Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery (NCT01754519) | Roswell Park Cancer Institute | 2013-05-01 |
| Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer (NCT01846091) | Mayo Clinic | 2013-04-09 |
| Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer (NCT01776008) | National Cancer Institute (NCI) | 2013-01-01 |
| Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer (NCT01750073) | University of Nebraska | 2012-12-07 |
| Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer (NCT01624441) | National Cancer Institute (NCI) | 2012-08-21 |
| Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer (NCT01575522) | National Cancer Institute (NCI) | 2012-03-01 |
| Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer (NCT01525966) | City of Hope Medical Center | 2012-02-15 |
| PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer (NCT01697293) | Prescient Therapeutics, Ltd. | 2012-01-01 |
| FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer (NCT01928186) | University of Washington | 2011-09-01 |
| MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer (NCT01319539) | National Cancer Institute (NCI) | 2011-04-01 |
| Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors (NCT01281150) | National Cancer Institute (NCI) | 2011-01-01 |
| Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery (NCT01276496) | National Cancer Institute (NCI) | 2010-12-01 |
| Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer (NCT01238133) | National Cancer Institute (NCI) | 2010-12-01 |
| RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer (NCT01149356) | National Cancer Institute (NCI) | 2010-10-01 |
| RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer (NCT01217411) | National Cancer Institute (NCI) | 2010-10-01 |
| Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer (NCT01145430) | National Cancer Institute (NCI) | 2010-06-01 |
| Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy (NCT00877500) | M.D. Anderson Cancer Center | 2009-03-30 |
| Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer (NCT00785291) | National Cancer Institute (NCI) | 2008-10-13 |
| Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive (NCT00390455) | National Cancer Institute (NCI) | 2006-09-15 |